Post-Conference Perspectives: Chronic Lymphocytic Leukemia

Experts share their perspective on the optimal management of chronic lymphocytic leukemia in light of recent clinical data for novel targeted therapies.

EP. 1: Revolutionizing the Management of Chronic Lymphocytic Leukemia

August 16th 2021

A comprehensive analysis of the CLL treatment landscape, including available agents, risk stratification, and triggers to initiate therapy.

EP. 2: Frontline BTK Inhibition in CLL: 7-Year Follow-up Data From RESONATE-2

August 16th 2021

Brad S. Kahl, MD, reflects on the 7-year follow-up data from the RESONATE-2 trial, which tested ibrutinib as frontline therapy in patients with CLL.

EP. 3: 4-Year Follow-up Data From ELEVATE-TN: Frontline Acalabrutinib in CLL

August 16th 2021

Insight on the 4-year follow-up data from ELEVATE-TN and the frontline use of acalabrutinib, with or without anti-CD20 therapy, in patients with CLL.

EP. 4: Head-to-Head Analysis of Acalabrutinib Vs Ibrutinib in Previously Treated CLL

August 16th 2021

Considerations for the head-to-head data out of ASCO 2021 comparing acalabrutinib and ibrutinib in previously treated chronic lymphocytic leukemia.

EP. 5: Optimal Toxicity Management With BTK Inhibitors in CLL

August 16th 2021

Brad S. Kahl, MD, shares practical advice on the management of BTK inhibitor–related toxicity in patients with chronic lymphocytic leukemia.

EP. 6: Moving the Dial on CLL Management: Sequencing Strategies and Unmet Needs

August 16th 2021

Before addressing unmet needs in the management of CLL, Brad S. Kahl, MD, outlines optimal sequencing strategies in the current treatment paradigm.

EP. 7: The Evolution of CLL Treatment

August 23rd 2021

Tara Graff, DO, MS, outlines the current treatment paradigm for chronic lymphocytic leukemia by discussing the use of novel agents, molecular testing, and risk stratification.

EP. 8: Rationale and Use of BTK Inhibitors as Initial Treatment for CLL

August 23rd 2021

A comprehensive breakdown of the rationale behind targeting BTK signaling in CLL, as well as considerations for clinical experience with the available BTK inhibitors.

EP. 9: Frontline BTKi Therapy in CLL: The ELEVATE-TN Study 4-Year Follow-up

August 23rd 2021

Expert insight on the use of frontline BTK inhibitor monotherapy over combination therapy in CLL regarding the ELEVATE-TN trial’s readout.

EP. 10: Acalabrutinib vs Ibrutinib: Head-to-Head Data in Previously Treated CLL

August 23rd 2021

Tara Graff, DO, MS, reflects on the head-to-head comparison data of acalabrutinib vs ibrutinib in patients with previously treated CLL.